ARA-290
Cibinetide
ARA-290 (Cibinetide) is a healing & recovery research compound. Non-erythropoietic EPO-derived peptide that activates the innate repair receptor — anti-inflammatory and nerve-repair without raising red cells.
ARA-290 quick facts
| Reported research dose | 1mg-4mg |
| Route | Subq |
| Frequency | 1x Daily · 5 On 2 Off or Daily |
| Half-life | ~2 min (plasma) |
| Forms | Injectable |
| Evidence level | Human trials (neuropathy) |
Neuropathic pain and repair angle with real human trial backing. Underrated.
How ARA-290 works
Non-erythropoietic EPO-derived peptide that activates the innate repair receptor — anti-inflammatory and nerve-repair without raising red cells.
Proposed benefits
Researched for soft-tissue and gut repair, reduced inflammation, angiogenesis and faster recovery from injury.
Where to get ARA-290
Buy ARA-290 at Flawless Compounds →The evidence for ARA-290
Graded by what exists behind each claim.
✅ Clinically validated
- Genuine randomized human trials — ARA-290 (cibinetide) was studied in sarcoidosis-associated small-fiber neuropathy and in type 2 diabetic neuropathy. In the largest trial (64 patients, 28 days), cibinetide significantly increased corneal nerve fiber area versus placebo (P = 0.012). Pain fell, but not significantly more than on placebo (P = 0.157).
- Development did not continue to approval. That is a funding and commercial outcome, not a refutation — the neuropathy signal was one of the more promising in a field with very little that works.
📊 Correlative data
- Small but consistent community use for neuropathic pain and inflammation, where reported experience tracks the trials — slow-building relief over weeks rather than an acute effect.
🧪 Theoretical / extrapolated
- An 11-amino-acid peptide derived from erythropoietin's helix B — it binds the innate repair receptor (EPOR/βcR heterodimer) rather than the classical EPO receptor.
- That receptor split is the entire design: it delivers EPO's tissue-protective and anti-inflammatory signaling without raising hematocrit, which is what makes EPO itself unusable for this purpose.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What ARA-290 actually does
ARA 290 is eleven amino acids cut out of the tertiary structure of erythropoietin, and the entire point of it is a receptor it does not hit. The sequence is pyroglutamate followed by Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser — a stretch of erythropoietin’s helix B that faces away from the surface EPO uses to bind its own receptor. Summing the residue masses gives about 1,257 Da, and the ionizable groups are three carboxylates — two glutamate side chains and the C-terminus — against one arginine, so the net charge at blood pH is −2 and the isoelectric point sits below pH 4. A small polyanion.
The receptor distinction is the drug. Erythropoietin acts through two different receptor assemblies. The EPOR homodimer drives erythropoiesis — that is the receptor that makes red cells and raises hematocrit. A second assembly, the innate repair receptor, pairs EPOR with the beta-common receptor, CD131, and mediates tissue protection rather than hematopoiesis. ARA 290 is described as interacting selectively with the innate repair receptor, distinct from the EPOR homodimers involved in hematopoiesis Brines 2015.
So this is a selectivity ratio expressed as a molecule: take the hormone, delete the surface that binds the erythropoietic assembly, and keep the one that binds the protective assembly. If it works, you get tissue protection with no rise in red cell mass — and that is a claim a person can test on themselves for the price of a blood count, which is unusual on this site.
The downstream pathway, measured rather than assumed. In LPS-activated macrophages, cibinetide’s effects were dependent on both CD131 and JAK2 functionality, and the mechanism identified was inhibition of the NF-kappaB subunit p65; the same work reported reduced myeloid cell infiltration, lower pro-inflammatory cytokines and chemokines, and reduced nitric oxide synthase-2 Nairz 2017. CD131 dependence is the experimental confirmation of the receptor story above — knock out the beta-common subunit and the drug stops working.
What the N-terminus buys chemically. The molecule begins with pyroglutamate, a cyclized glutamate with no free alpha-amine. Aminopeptidases attack free N-terminal amines; there is not one here. That is the same protective trick as an acetyl cap, achieved by ring formation instead, and it is why an 11-residue peptide is dosed once a day rather than continuously.
Cell, rodent, human — and where it stops
Step one, in cells, with the receptor knocked out. LPS-activated macrophages; the anti-inflammatory effect required CD131 and JAK2; NF-kappaB p65 activity was inhibited Nairz 2017.
Step two, in rats, and the durability number is the striking one. Spared nerve injury model, ARA 290 at 3, 10, 30 or 60 micrograms per kilogram on days 1, 3, 6, 8 and 10 — five doses, then nothing. Mechanical allodynia was significantly reduced against vehicle for up to 20 weeks, and cold allodynia at every dose from 3 to 60 micrograms per kilogram for 20 weeks. Spinal microglial reactivity, measured as iba-1 immunoreactivity, was prevented at 10 or 30 micrograms per kilogram at the 2-week timepoint, and at 20 weeks the 30 microgram group showed no increase against sham. There was no difference in astrocyte reaction Swartjes 2014.
Step three, in mice, two different organs. DSS-induced colitis: cibinetide improved the clinical course, weight gain and survival Nairz 2017. Bone: one month of treatment raised cortical bone mineral density by about 5.8% and trabecular by about 5.2% in female C57BL/6J mice, and in a 5-day protocol osteoclast progenitors fell 42.8% against EPO alone Awida 2021.
Step four, humans, study one, which met its primary endpoint. Adults with type 2 diabetes given ARA 290 at 4 mg subcutaneously daily for 28 days, followed by a 28-day observation period. The primary endpoint was the mean change in HbA1c from baseline across the 56-day period, and it was met — the treated group showed improvement in HbA1c and in lipid profiles. Neuropathic symptoms improved significantly on the PainDetect questionnaire, and corneal nerve fiber density increased significantly in the subjects whose baseline density was more than one standard deviation below normal. No safety issues were identified. Nine patients were enrolled Brines 2015.
Step five, humans, study two, which missed every primary endpoint. A phase 2 in diabetic macular edema: 4 mg per day subcutaneously for 12 weeks, 9 enrolled and 8 completed. Baseline to week 12: best-corrected visual acuity −2.9 ± 5.0, central retinal thickness +10 ± 94.6 microns, central retinal sensitivity −0.53 ± 1.9 dB, tear production −0.13 ± 7.7 mm — no improvement in any of them. The composite score on the NEI VFQ-25 quality-of-life questionnaire improved by 2.7 ± 3.1. No serious adverse events and no anti-cibinetide antibodies detected Lois 2020.
Put the two human trials side by side, because that is the honest picture of this compound. Eighteen people enrolled between them and seventeen finished. One trial hit a metabolic primary endpoint in nine of them; the other missed four ophthalmic primary outcomes in nine of them, at the same dose, in the same disease, for three times as long. Neither result is strong enough to overturn the other, and the compound’s reputation rests almost entirely on the first.
The obstacles, one at a time. (1) Both human trials enrolled 9 people Brines 2015 Lois 2020. (2) The corneal nerve result was confined to a subgroup defined by baseline deficit, which is the group with the most room to regress toward the mean Brines 2015. (3) The 20-week durability in rats came from five doses over ten days Swartjes 2014, and no human protocol has ever been designed that way. (4) There is no published human pharmacokinetic study of ARA 290 at all. (5) The bone and colitis results are mouse-only Awida 2021 Nairz 2017 and neither has any human counterpart.
ARA-290 pharmacokinetics — how much of it actually gets in
What is protected and what is not. The pyroglutamate N-terminus has no free alpha-amine, so aminopeptidase N — the fastest route of attack on a short peptide and abundant on the endothelium a subcutaneous dose must cross — cannot start. The C-terminus is Ser-Ser with a free carboxylate, which leaves carboxypeptidases an open handle, and there are no D-amino acids anywhere in the chain to interrupt endopeptidase recognition. Protected at one end, undefended at the other.
What clears it. At about 1,257 Da with a net charge of −2, this peptide is more than forty times below the glomerular filtration cut-off and binds nothing that would hold it in plasma. Renal filtration plus proteolysis is the whole story, and for an unmodified 11-mer that means a plasma residence measured in minutes to a very small number of hours. Both human trials dosed once daily Brines 2015 Lois 2020, which is consistent with that and does not measure it.
And here is the part that makes the half-life almost irrelevant. In rats, five doses across ten days produced relief of mechanical and cold allodynia that was still significant at 20 weeks Swartjes 2014. Whatever this molecule’s plasma half-life is, the pharmacodynamic effect outlasted the pharmacokinetic exposure by something on the order of a hundredfold. That is the signature of a compound that starts a process — in this case suppression of the spinal microglial response, which was still absent at 20 weeks Swartjes 2014 — rather than one that maintains an effect while present.
Why that matters practically, and it is unstated anywhere. Both human protocols dosed 4 mg every day for 28 days or 12 weeks Brines 2015 Lois 2020, which is a maintenance design. The rodent evidence supports an induction design. Nobody has tested whether five doses would have done what twenty-eight did, and the difference is a factor of five or six in cost and exposure.
Immunogenicity, which is a pharmacokinetic question for a peptide. After 12 weeks of daily subcutaneous dosing, no anti-cibinetide antibodies were detected Lois 2020. Anti-drug antibodies are the usual reason a peptide stops working over months, and this is one of the few compounds in this catalog with an actual negative result on that question.
The oral barrier and the route. Absolute; subcutaneous. An 11-residue dianion has no passive route across the gut and would meet pancreatic proteases first in any case.
What would have to be true, and how you would know it was not
Four predictions. The first is the identity test that this compound’s whole design makes available, and the third argues against it.
1. Hemoglobin, hematocrit and the reticulocyte count must not rise. This is the defining test. The molecule was built to activate the innate repair receptor and not the EPOR homodimer that drives erythropoiesis Brines 2015. Draw a CBC with a reticulocyte count at baseline and at 8 weeks. Reticulocytes respond within days and are the sensitive early marker; hematocrit follows over weeks. A rise in either is not a bonus — it is evidence that the vial contains something other than ARA 290, because the one thing this peptide is engineered not to do is make red cells. That is the cheapest and most decisive identity check on any page in this cohort.
2. HbA1c and the lipid panel should improve modestly, and the evidence for that is nine people. The registered trial’s primary endpoint was mean change in HbA1c over 56 days and it was met, with lipid profiles improving alongside Brines 2015. Draw HbA1c and a lipid panel at baseline and 12 weeks. Treat a null result as entirely compatible with the evidence: a nine-person study is a reason to look, not a reason to expect.
3. Nothing ophthalmic will change in 12 weeks, and this cuts against the compound. The phase 2 in diabetic macular edema missed all four of its primary outcomes at exactly this dose over exactly this duration: acuity, retinal thickness, retinal sensitivity and tear production Lois 2020. Anyone taking this for an eye or a dry-eye indication is running a protocol that has already been tried and did not work.
4. The neuropathy read-out, which has no blood marker. What to watch: a nightly 0–10 score for burning or tingling in the same anatomical area, recorded at the same time, plus a monthly count of nights woken by it — the trial that found an effect used a structured symptom questionnaire, not a blood test Brines 2015. How long before it means anything: the registered protocol ran 28 days of dosing plus 28 days of observation before reading its endpoint Brines 2015, and the rat data suggest the effect keeps developing after dosing stops Swartjes 2014 — so eight weeks from the first dose, not two. What will fool you: glycemic control itself. Neuropathic symptoms track glucose variability closely, and the same trial reported HbA1c improving Brines 2015 — so a symptom change during a period when glucose also improved cannot be attributed to the peptide at all.
What nobody has tested yet
Five experiments. The second one would change how the compound is dosed by everyone using it.
1. Nobody has measured this peptide in human plasma. There is no published time to peak, no maximum concentration, no half-life and no bioavailability for ARA 290 by any route, in any human study Brines 2015 Lois 2020. The 4 mg daily dose that both trials used was therefore chosen without a human exposure curve behind it.
2. Nobody has tested induction dosing against maintenance dosing. Five doses over ten days gave rats twenty weeks of effect Swartjes 2014; humans have only ever been given it daily for four to twelve weeks Brines 2015 Lois 2020. A two-arm study — five doses versus twenty-eight, same total observation — is cheap, is directly suggested by the animal data, and would tell every user whether they are taking five times more drug than they need.
3. Nobody has looked at bone in a human. One month of cibinetide raised murine cortical bone mineral density about 5.8% and cut osteoclast progenitors 42.8% Awida 2021. Adding bone-turnover markers to any existing human protocol would cost almost nothing, and both effect directions matter — a bone-sparing effect would be a genuine second indication, and chronic osteoclast suppression is a known way to make bone worse over years.
4. Nobody knows whether it repairs nerves or only rescues depleted ones. The corneal nerve fiber density gain appeared only in subjects starting more than one standard deviation below normal Brines 2015. Whether someone with normal baseline density gains anything is unmeasured, and it is the difference between a repair drug and a rescue drug.
5. Nobody has tested the infection question. This peptide dampens innate immune cell function, reduces myeloid infiltration and inhibits NF-kappaB p65 Nairz 2017. Those are the same mechanisms that clear bacteria. No study in any species has challenged a cibinetide-treated animal with an infection, and for a drug proposed for chronic use that is the obvious missing arm.
ARA-290 — its own safety story, not its class's
The class block on this page is written for injectable repair peptides. Five things below are this molecule’s own.
1. The thing it was designed not to do is the thing to verify. Erythropoietin raises hematocrit, and raised hematocrit is a thrombotic risk. ARA 290 is specifically the fragment that does not engage the erythropoietic receptor assembly Brines 2015. A CBC before and during use is therefore not a generic precaution on this compound — it is the direct test of whether the molecule in the vial is the one described in the literature.
2. Immune dampening is the mechanism, so it is also the risk. Reduced myeloid infiltration, lower pro-inflammatory cytokines and chemokines, reduced nitric oxide synthase-2 and inhibited NF-kappaB p65 Nairz 2017 are a good description of an anti-inflammatory drug and an equally good description of an impaired acute response to bacteria. No infection-challenge study exists in any species, and this is the risk that belongs on this page instead of the class’s generic angiogenesis warning.
3. Bone, in both directions. Osteoclast progenitors fell 42.8% and bone mineral density rose about 5% in mice after a month Awida 2021. Nobody has taken that to a human. Sustained osteoclast suppression is the mechanism behind the rare long-term problems seen with antiresorptive drugs, and a month in a mouse says nothing about years in a person.
4. The published human safety record, sized honestly. Eighteen people enrolled, seventeen completed, across two trials Brines 2015 Lois 2020. No safety issues in the 28-day study, no serious adverse events and no anti-drug antibodies in the 12-week study. That is a clean record and it is a very small one; nothing about seventeen people over twelve weeks addresses uncommon events or chronic use.
5. What the missed trial actually tells you about risk. A phase 2 that misses all four primary outcomes Lois 2020 is usually read as a disappointment. Read it as a safety datum as well: twelve weeks of daily 4 mg subcutaneous dosing in people with diabetic eye disease produced no serious adverse events and no measurable immunogenicity, which is more useful exposure information than most compounds on this site have at any dose.
Sources read for this page
- Brines M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine 2015 · PMID 25387363
- Swartjes M, et al. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Molecular Pain 2014 · PMID 24529189
- Lois N, et al. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of Clinical Medicine 2020 · PMID 32674280
- Nairz M, et al. Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. Scientific Reports 2017 · PMID 29026145
- Awida Z, et al. The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International Journal of Molecular Sciences 2021 · PMID 35008482
ARA-290 — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Repair peptides work by promoting angiogenesis — new blood vessel growth — plus fibroblast migration and growth-factor signaling. That is what makes them useful, and it is the entire basis of the one theoretical concern worth naming: angiogenesis is also what a tumor needs to grow beyond a few millimetres.
- There is no evidence these compounds cause or accelerate cancer. There is a mechanistic reason not to run a pro-angiogenic agent systemically with an active or recently treated malignancy, and that reasoning stands without a trial.
- The second predicted issue is more mundane and more likely: they can mask a signal. Something that reduces pain and inflammation around an injury lets you load a tissue that has not finished healing.
What has actually been reported
- Very well tolerated in reported use. Injection-site reactions and transient light-headedness are the common complaints.
- Human data is thin — most of the literature is rodent — so 'well tolerated' here means 'no signal has emerged from a lot of informal use', which is weaker than a clean trial and stronger than nothing.
How to reduce the risk
Same mechanism as the prediction.
- Stop when the thing you were treating has resolved. There is no mechanism here that demands a clock, and equally no reason to keep running a pro-angiogenic signal once the job is done.
- Get the diagnosis before the peptide. These accelerate healing of things that heal. A tear that needs surgical repair does not become a tear that does not, and the delay costs you.
- One injury, one compound, long enough to judge it. Otherwise you learn nothing transferable for next time.
What it does to your bloodwork
A fact about the assay.
- Nothing routine tracks these directly. The endpoint is the injury, which means your own honest assessment of function is the measurement.
Don't run this if
- Any undiagnosed lump or lesion. Find out what it is first.
The honest unknown
- Long-term systemic exposure in humans has never been characterized. The use case is naturally self-limiting — you stop when the injury resolves — which is why this matters less here than it would elsewhere.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
ARA-290 — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What ARA-290 moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
If a repair peptide is doing anything systemic, inflammation is where it would plausibly show.
What to do: Worth a baseline if you are running one for a chronic issue rather than an acute injury. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Standard baseline. Nothing in this class predicts a specific abnormality — which is itself worth saying rather than inventing one.
What to do: Annual is fine unless something changes.
The honest position on this class is that the proliferation question is unresolved — anything that accelerates tissue repair is acting on pathways cancer also uses. Nobody has studied it properly either way.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — ARA-290 in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside ARA-290
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Baseline inflammation — the thing you're claiming to reduce |
| Complete Blood Count (CBC) with Differential | Infection, anemia and platelet count before anything injectable |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
| Vitamin D (25-Hydroxy) | Low D slows soft-tissue and bone healing measurably |
The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.
Check results you already have → · All 103 markers A–Z
ARA-290 — frequently asked questions
What is ARA-290?
ARA-290 (Cibinetide) is a healing & recovery research compound. Non-erythropoietic EPO-derived peptide that activates the innate repair receptor — anti-inflammatory and nerve-repair without raising red cells.
Is the full ARA-290 protocol on this page?
The reported research dose is on this page, along with how ARA-290 works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of ARA-290?
ARA-290 has an approximate half-life of ~2 min (plasma), which is part of what determines how often it's dosed.
What's the evidence behind ARA-290?
Current evidence level: Human trials (neuropathy). ARA-290 is offered for research purposes only and is not an approved medicine.
ARA-290 inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What ARA-290 is used for
ARA-290 appears under 3 goals in the goal router.
Related Healing & Recovery compounds
Where this goes next
ARA-290 is the angiogenesis arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.